The company was able to ramp up recruitment for its pivotal ECLIPSE trial after hurdles caused a falloff during the earlier months of the COVID-19 pandemic.
The assay provides comprehensive genomic information to oncologists from a blood draw, using targeted next-generation sequencing of circulating cell-free DNA.
Researchers used the system to precisely deplete mRNA transcripts in zebrafish embryos and showed that it can also be used in medaka, killifish, and mouse.
The report also identified opportunities to improve adoption through dissemination of evidence supporting the clinical and economic utilization of testing.
